

Attorney Docket No.: UT-0030
Inventors: Rao et al.
Serial No.: 09/736,728
Filing Date: December 14, 2000
Page 2

Amendments to the claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 6.

Attorney Docket No.: UT-0030
Inventors: Rao et al.
Serial No.: 09/736,728
Filing Date: December 14, 2000
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-12 (canceled)

Claim 13 (currently amended): A method of obtaining glial cells comprising:

(a) providing glial restricted precursor cells which are immunonegative for PDGF- α and PDGF- β receptors, which express A2B5 antigen and which are isolated by positive immunoselection with an A2B5 antibody selecting cells expressing A2B5 antigen; and

(b) plating the glial restricted precursor cells provided in step (a) under differentiating conditions, thereby causing the glial restricted precursor cells expressing A2B5 antigen which are immunonegative for PDGF- α and PDGF- β to differentiate into glial cells.

Claim 14 (original): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of a factor that promotes differentiation into non-process bearing A2B5⁻GFAP⁺ astrocytes and said glial cells are A2B5⁻GFAP⁺ astrocytes.

Claim 15 (original): The method of claim 14 wherein said

Attorney Docket No.: UT-0030
Inventors: Rao et al.
Serial No.: 09/736,728
Filing Date: December 14, 2000
Page 4

factor that promotes differentiation into non-process bearing A2B5⁻ GFAP⁺ astrocytes comprises fetal calf serum.

Claim 16 (original): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of a factor that promotes differentiation into process bearing A2B5⁺GFAP⁺ astrocytes and said glial cells are A2B5⁺GFAP⁺ astrocytes.

Claim 17 (original): The method of claim 16 wherein said factor that promotes differentiation into process bearing A2B5⁺GFAP⁺ astrocytes comprises ciliary neurotrophic factor and basic fibroblast growth factor.

Claim 18 (original): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of a factor that promotes differentiation into oligodendrocytes and said glial cells are oligodendrocytes.

Claim 19 (original): The method of claim 18 wherein said factor that promotes differentiation into oligodendrocytes comprises platelet-derived growth factor and thyroid hormone (T3).

Claims 20-48 (canceled)

Claim 49 (currently amended): A method for continuously propagating glial restricted precursor cells immunonegative for PDGF- α and PDGF- β comprising the steps of:

Attorney Docket No.: UT-0030
Inventors: Rao et al.
Serial No.: 09/736,728
Filing Date: December 14, 2000
Page 5

(a) providing said glial restricted precursor cells which are immunonegative for PDGF- α and PDGF- β receptors, which express A2B5 antigen and which are isolated by positive immunoselection with an A2B5 antibody ~~selecting cells expressing A2B5 antigen;~~ and

(b) culturing said glial restricted precursor cells provided in step (a) *in vitro* in the presence of minimal essential salts and effective amounts of platelet derived growth factor and fibroblast growth factor.